RGEN vs. QGEN, XLRN, CRSP, TECH, BIIB, ALNY, BMRN, NBIX, INCY, and UTHR
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Qiagen (QGEN), Acceleron Pharma (XLRN), CRISPR Therapeutics (CRSP), Bio-Techne (TECH), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Repligen (NASDAQ:RGEN) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
In the previous week, Repligen had 4 more articles in the media than Qiagen. MarketBeat recorded 9 mentions for Repligen and 5 mentions for Qiagen. Repligen's average media sentiment score of 1.01 beat Qiagen's score of 0.97 indicating that Repligen is being referred to more favorably in the media.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
97.6% of Repligen shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Repligen received 156 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.08% of users gave Repligen an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Qiagen has a net margin of 17.38% compared to Repligen's net margin of 2.44%. Qiagen's return on equity of 12.59% beat Repligen's return on equity.
Repligen currently has a consensus price target of $197.75, suggesting a potential upside of 32.64%. Qiagen has a consensus price target of $50.95, suggesting a potential upside of 17.77%. Given Repligen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Qiagen.
Summary
Repligen beats Qiagen on 11 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
